Prostate cancer research focuses on active surveillance, precision medicine, hormone therapy innovations, and minimally invasive treatments.
EXTEND was an investigator-initiated, multicenter, open-label, six-basket phase II randomized trial of metastasis-directed therapy (MDT) added to standard of care (SOC) in oligometastatic solid tumors. In the aggregated per-protocol population (n = 334; 166 vs 168), progression-free survival favored MDT + SOC: HR 0.54 (95% CI 0.41 to 0.72), P < .001, with median PFS 25.40 vs 14.00 months at a median follow-up of 53 months.
PATHFINDER 2, a prospective, interventional cohort study of 35,878 adults aged 50 and older with no clinical suspicion of cancer, evaluated the performance and safety of a blood-based multi-cancer early detection (MCED) test that analyzes cell-free DNA methylation patterns to detect a shared cancer signal and predict its tissue of origin.
A registry-based analysis of 11,681 US interventional cancer trials registered on ClinicalTrials.gov between 2008 and 2024 found that industry sponsors now outnumber federal sponsors nearly 5 to 1 (4.53-to-1 overall), with the ratio widening from 2.72-to-1 in 2008–2012 to 6.44-to-1 in 2019–2024.
A retrospective cohort study of 16,924 men with prostate cancer, drawn from the Epic Cosmos national electronic health record dataset, found that new-onset metabolic syndrome developed in nearly 40% of patients within 12 months of starting concurrent androgen deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI).
A first-cycle "adaptive therapy score," derived from a mathematical model of competing drug-sensitive and drug-resistant tumor cell populations, more strongly predicted time to progression than any standard PSA metric across two independent prostate cancer cohorts (n=53 total).